Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
189 hedge funds and large institutions have $1.07B invested in Eagle Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 80 increasing their positions, 42 reducing their positions, and 21 closing their positions.
90% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 42
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
15% more call options, than puts
Call options by funds: $18.7M | Put options by funds: $16.3M
3% more funds holding
Funds holding: 183 → 189 (+6)
1.31% less ownership
Funds ownership: 103.59% → 102.29% (-1.3%)
8% less capital invested
Capital invested by funds: $1.16B → $1.07B (-$95.3M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$23.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$21.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$9.57M |
| 4 |
MCM
Matarin Capital Management
New York
|
+$7.38M |
| 5 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$5.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
-$38.2M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$27.5M |
| 3 |
Lazard Asset Management
New York
|
-$24.4M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$11.8M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$6.79M |
EGRX Hedge Fund Activity: Q3 2018 in Review
189 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2018, worth a combined $1.07B — down 8.2% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new EGRX positions and 21 closed out — a net gain of 8 holders — while 80 added to existing stakes and 42 trimmed.
The largest buyer was BlackRock, adding an estimated $23.5M. The largest seller was LSV Asset Management, cutting an estimated $38.2M.
- 189 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2018, up from 183 in Q2 2018.
- Funds reported $1.07B of Eagle Pharmaceuticals, Inc. stock for Q3 2018, down 8.2% quarter-over-quarter.
- 29 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2018 and 21 closed out, a net change of +8 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2018 was BlackRock, an estimated $23.5M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q3 2018 was LSV Asset Management, an estimated $38.2M sold.
Based on aggregated 13F filings for Q3 2018.